A5049353036- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Urinary and Genital Oncology Studies
- Chemotherapy-induced organ toxicity mitigation
- Nausea and vomiting management
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Smoking Behavior and Cessation
- Gestational Trophoblastic Disease Studies
- Chemotherapy-related skin toxicity
- Full-Duplex Wireless Communications
- Inflammatory Biomarkers in Disease Prognosis
- Air Quality and Health Impacts
- Thyroid Cancer Diagnosis and Treatment
Carlo Forlanini Hospital
2017-2021
Istituto Tumori Bari
2019-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
Ospedale A. Perrino
2020
Sapienza University of Rome
2012-2019
Cancer Research Center
2019
Nini Hospital
2018
Policlinico Umberto I
2012-2017
Abstract Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow any conclusive consideration. Liquid biopsy might real-time sampling patients PD-L1 through course disease. Twenty-four stage IV NSCLC included Expanded Access Program with Nivolumab were enrolled. Circulating cells (CTCs) analyzed by CellSearch anti-human B7-H1/PD-L1 PE-conjugated antibody. expressing CTCs assessed...
Tregs can contribute to tumor progression by suppressing antitumor immunity. Exceptionally, in human colorectal cancer (CRC), are thought exert beneficial roles controlling pro-tumor chronic inflammation. The goal of our study was characterize CRC-infiltrating at multiple levels, phenotypical, molecular and functional evaluation from the site, compared non-tumoral mucosa peripheral blood CRC patients. frequency higher than blood, further significantly increased tumor. Ex vivo, those...
Background: MIBC is an aggressive disease, with 5-year survival rates ranging from 36 to 48% for p T3/p T4/p N+tumors. Perioperative treatment can improve overall survival, more robust evidence in favor of neoadjuvant chemotherapy. Few randomized studies have compared and adjuvant therapy bladder cancer. Consequently, it has been difficult establish the benefit chemotherapy (AC) MIBC. Methods: Data patients muscle invasive cancer (>pT2) collected 2005 2012 within RISC data base...
Introduction: With repeated courses of chemotherapy, chemotherapy-induced nausea and vomiting (CINV) becomes progressively more difficult to control. The aim this study was evaluate whether the antiemetic efficacy triple combination aprepitant, palonosetron dexamethasone could be sustained for up six cycles highly emetogenic chemotherapy (HEC) (cisplatin ≥ 50 mg/m(2) ). Methods: Chemotherapy-naive patients receiving cisplatin-based HEC, were treated with 0.25 mg/i.v., 20 mg/i.v. aprepitant...
In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy not defined. We evaluated clinical response survival outcomes advanced LCNEC treated in first-line compared SCLC. 72 patients stage III–IV (n=28) extensive-stage SCLC (ES-SCLC) (n=44) received cisplatin–etoposide with/without thoracic (TRT) prophylactic cranial irradiation...
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the final stage of pCa history and represents a clinically relevant phenotype with an elevated burden mortality. The aim present study was to evaluate efficacy safety enzalutamide in "real-life" setting mCRPC patients.METHODS: Data about all patients treated from September 2017 2018 were collected. Demographics, comorbidities, clinical parameters, outcomes, toxicity, overall survival progression free analyzed.RESULTS:...
Merkel cell carcinoma (MCC) is an extremely rare primary neuroendocrine neoplasm of the skin that shows aggressive behavior and a poor prognosis. We report case 67-year-old male with which initially presented itself as large retroperitoneal mass. Pathological immunohistochemical analysis revealed tissue consistent carcinoma. Despite complete medical workup, no other MCC could be detected. While being atypical presentation, tumor mass showed excellent response to combination chemotherapy...
4577 Background: Nivolumab showed a survival benefit in randomised phase III trial pre-treated mRCC. The EAP provided the opportunity to treat patients (pts) real world clinical practice before market availability of drug practice. aim this analysis was evaluate safety and activity nivolumab setting. Methods: available upon physician request for pts aged ≥18 years who had relapsed after minimum one prior systemic treatment 3 mg/kg administered intravenously every 2 weeks. Pts included...
Background: Second-line immunotherapy showed an overall survival (OS) benefit, but only a low percentage of aNSCLC patients (pts) respond to therapy. The identification new biomarkers select for (IO) is crucial topic. In our study we aim investigate the role peripheral blood (PBBs) that can predict response and outcome in pts treated with IO. Methods: We conducted retrospective analysis on 154 receiving single-agent nivolumab or pembrolizumab as second-line (68%) >3rd line (32%) recorded...
Metastasis to the esophagus from a distant primary location is rare manifestation in patients with NSCLC presenting obstructive upper gastrointestinal symptoms. Oftentimes, placement of stent across stricture provides partial resolution symptoms.1Simchuk E.J. Low D.E. Direct esophageal metastasis tumor submucosal process: review six cases.Dis Esophagus. 2001; 14: 247-250Crossref PubMed Scopus (34) Google Scholar,2Oka T. Ayabe H. Kawahara K. et al.Esophagectomy for metastatic carcinoma lung...
e14096 Background: The aim of this retrospective study is to define the usefullness an integrated CT software that automatically generates report according RECIST 1.1 criteria and Choi criteria, evaluating effects bevacizumab based chemotherapy on CRC liver metastases. Methods: 35 patients with a total 144 metastases underwent before after treatment. Patients peritoneal disease were excluded. Reporting time was recorded for all patients. images reviewed by two radiologists in consensus,...